RELX•RELX said it targets continued improvement in Scientific, Technical & Medical revenue growth, with adjusted operating profit growth remaining ahead of revenue growth. Underlying STM revenue rose 6% in H1 2026 and adjusted operating profit increased 8%.
RELX said its Scientific, Technical & Medical division accounted for 28% of group revenue in H1 2026, with subscriptions generating 78% of sales. Elsevier article submissions grew more than 20%, while published articles increased 7%.
The Primary Research strategy prioritizes higher publication volumes at a lower effective price. Decision Support growth centers on faster product innovation.
